Moreover, early-phase clinical trials testing PERK inhibitors or activators—either alone or in combination with chemotherapy or immunotherapy—are warranted to evaluate their therapeutic potential and safety in CRC patients. Here, EIF2AK3 is linked to colorectal carcinoma.